Previous Close | 0.2249 |
Open | 0.2299 |
Bid | 0.2130 x 1200 |
Ask | 0.2161 x 1200 |
Day's Range | 0.2100 - 0.2350 |
52 Week Range | 0.2100 - 1.4600 |
Volume | |
Avg. Volume | 3,184,745 |
Market Cap | 55.371M |
Beta (5Y Monthly) | 0.34 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1680 |
Earnings Date | May 16, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.25 |
Subscribe to Yahoo Finance Plus to view Fair Value for NMTR
A medical device company that set up shop in Chapel Hill last year has received some relief in its bid to remain listed on the Nasdaq Capital Market.
Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel SyndromeRALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced it has entered into a senior secured convertible notes facility with a single lender for up to $70 million that is part of an overall financing strategy to support the continued develop
(NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced positive preliminary topline results from the VIBRANT study (VurolenatIde for short Bowel syndrome Regardless of pArenteral support requiremeNT), its Phase 2 trial of vurolenatide, a proprietary, long-acting GLP-1 receptor agonist in development for the treatment of adult patients with short bowel syndrome (SBS). Based on positive results from this Phase 2